Quince Therapeutics (QNCX) EPS (Diluted) (2021 - 2026)
Powered by 
Analysis
Quince Therapeutics (QNCX) EPS (Diluted) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 4.37 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 4.31 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 12.23 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 7.15 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -1.96 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.19 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -0.40 |
| 10 | Quince Therapeutics | 175.52 Mn | 175.52 Mn | - | -12.31 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -12.31 |
| Mar 31, 2026 | 71.37 |
| Dec 31, 2025 | -76.98 |
| Sep 30, 2025 | -49.83 |
| Jun 30, 2025 | -68.75 |
| Mar 31, 2025 | -68.41 |
| Dec 31, 2024 | -57.80 |
| Sep 30, 2024 | -25.45 |
| Jun 30, 2024 | -128.68 |
| Mar 31, 2024 | -51.84 |
| Dec 31, 2023 | -47.77 |
| Sep 30, 2023 | -29.67 |
| Jun 30, 2023 | -27.21 |
| Mar 31, 2023 | -68.35 |
| Dec 31, 2022 | -33.04 |
| Sep 30, 2022 | -44.48 |
| Jun 30, 2022 | -102.04 |
| Mar 31, 2022 | -143.63 |
| Dec 31, 2021 | 447.84 |
| Sep 30, 2021 | -145.84 |